top of page

No-Exam Term Life Insurance After Squamous Cell Skin Cancer: When It's "Skin-Only"

Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.

Squamous cell carcinoma (SCC) of the skin is often treatable, but underwriting will look for details that confirm it stayed localized and that treatment is complete.

  • Instant online pricing

  • No phone calls required

  • No pressure from agents

SCC: Underwriting Focuses on "Skin-Only" vs Complicated

Treatment type and dates (excision/Mohs) and pathology notes

Recurrence history and how often lesions have appeared

Any indication it wasn't skin-only (deeper spread or aggressive features)

When people ask about no-exam term life insurance and squamous cell skin cancer, they are usually talking about a localized skin lesion that was surgically removed - but underwriting draws an important distinction between SCC in situ and invasive SCC. SCC in situ, sometimes called Bowen's disease, means the abnormal cells are confined entirely to the epidermis and have not penetrated into the dermis below; this is generally treated as lower-risk. Invasive SCC, by contrast, has breached the dermal layer and carries a meaningful risk of regional lymph node spread, particularly when certain high-risk features are present. That distinction - in situ versus invasive - is often the first question underwriters ask when SCC appears on an application.

When the SCC was invasive, carriers may ask about specific pathology features associated with higher recurrence rates and metastatic potential. These high-risk features include perineural invasion (tumor cells growing along nerve sheaths), lesion size greater than two centimeters, poorly differentiated histology (meaning the tumor cells look less like normal skin cells under the microscope), and anatomical location on the head, neck, or ears - areas where tissue planes are complex and surgical margins are harder to achieve. Each of these features individually increases scrutiny; a case combining several of them may require attending physician statements or detailed dermatology records before underwriting can finalize a decision. Differentiation grade - well, moderately, or poorly differentiated - is recorded directly in the pathology report, and poorly differentiated SCC is consistently flagged as higher-risk in standard underwriting manuals, so having that report available avoids delays from records requests.

Immunosuppressed applicants face a different baseline than the general population. Transplant patients maintained on tacrolimus or cyclosporine develop SCC at rates that are dramatically elevated, and their SCCs often behave more aggressively - with higher recurrence rates, faster growth, and greater lymph node risk. Carriers are aware of this and may apply separate underwriting guidelines for applicants whose SCC history occurs in the context of transplant immunosuppression or other immune-modifying conditions such as long-term systemic corticosteroid use. If you are in this category, expect questions about both the SCC and the underlying condition driving the immunosuppression, because the two histories are evaluated together rather than independently when assessing future recurrence and surveillance needs.

Surgical margins are a direct underwriting data point. A pathology report showing clear margins - meaning no tumor cells at the edges of the excised tissue - signals that the lesion was fully removed. Close or involved margins on the pathology report typically prompt additional excision or adjuvant treatment, and until that follow-up is documented and completed, underwriting generally treats the case as unresolved. If you had a re-excision or additional treatment after an initial close-margin result, having documentation of the final clear-margin confirmation is the most useful piece of evidence you can provide to move underwriting forward, because carriers want to see a closed loop: lesion identified, removed with clear margins, followed up, no recurrence.

A simple summary helps keep the process moving: the diagnosis date, whether the SCC was in situ or invasive, the treatment type and date, whether final pathology confirmed clear margins, and whether there have been any recurrences or additional SCC lesions since the original treatment. If you are on a routine dermatology surveillance schedule, noting that your last check was clear and when the next appointment is scheduled gives underwriting a current clinical anchor rather than leaving the story open-ended. Applicants who provide a clean, documented timeline typically reach a decision faster than those whose records have to be assembled piecemeal by the carrier's underwriting team, because the relevant facts are already organized rather than spread across multiple record requests that each add days to the review.

For the full no-exam term life overview and how accelerated underwriting typically works, see: https://www.careproinsurance.com/instant-term-life-insurance

None of the information here is intended as professional legal, medical, or financial counsel. Quotes are estimates and final eligibility/pricing depend on underwriting and the issued policy language.

Frequently Asked Questions

Can I get no-exam term life insurance with a history of squamous cell skin cancer?

Often, yes, depending on timing and whether the SCC was localized and treated. Carriers may ask for treatment details and follow-up information. Underwriting applies.

What does "skin-only" SCC mean for life insurance?

It generally refers to a localized lesion treated on the skin without evidence of deeper spread. Underwriting may still verify treatment and follow-up.

Does recurring SCC affect underwriting?

It can. Multiple lesions or frequent recurrences may lead to additional questions or different underwriting outcomes depending on timing and overall profile.

Will SCC automatically raise my premium?

Not necessarily. Many applicants can still qualify for competitive rates. Outcomes depend on timing, recurrence history, and overall health.

What should I have ready before applying?

Helpful details include diagnosis/treatment dates, type of treatment, any pathology notes you have, and whether there have been recurrences or ongoing treatment.

What is the difference between SCC in situ and invasive SCC for underwriting purposes?

SCC in situ is confined to the epidermis and has not penetrated deeper tissue, which carriers typically treat as lower-risk. Invasive SCC has grown into the dermis and carries higher potential for regional spread, so it may prompt more detailed questions about pathology features and surgical margins.

Why does the anatomical location of an SCC matter to underwriters?

Lesions on the head, neck, or ears are considered higher-risk because those areas have complex tissue planes, are closer to lymph node drainage basins, and are associated with higher rates of local recurrence and regional spread than lesions on the trunk or extremities. Carriers may ask about location specifically when evaluating an invasive SCC history.

Can perineural invasion on a pathology report affect my life insurance application?

Yes. Perineural invasion - tumor cells growing along nerve sheaths - is a recognized high-risk feature associated with higher recurrence rates and greater potential for regional spread. Underwriters may flag it as a reason for additional documentation or a more detailed review of your post-treatment surveillance history.

Get Covered With The Right Plan

Clarify the difference between a typical skin-only SCC history and cases that trigger deeper review because of recurrence, aggressive features, or more extensive treatment.

Get term life quotes

bottom of page